The Use of a Combination Vaccine in International Travelers Visiting Countries with High Endemic Rates of Hepatitis A and/or Hepatitis B
Bradley A. Connor1, Susan Anderson2 & Robert Steffen3 Show affiliations
- The Weill Medical College of Cornell University, United States
- Stanford University School of Medicine, United States
- University of Zurich Travel Health Center, Switzerland
American Journal of Infectious Diseases, Volume 4, Issue 2, pp. 104–108 · doi.org/10.3844/ajidsp.2008.104.108
Abstract
Hepatitis A and B represent a significant threat to international travelers. Both diseases are preventable through vaccination, though fewer than half of at-risk visitors in endemic regions are protected. Current vaccination recommendations should be revised to ensure adequate immunity for all international travelers against hepatitis A and B, as both diseases pose comparable danger. Since exposure to the viruses cannot be predicted, vaccination should be offered to all individuals visiting destinations with intermediate or high endemicities of hepatitis A and/or B, regardless of length of stay and standard of accommodation. Risk groups and endemicity of hepatitis A and B overlap, therefore, a combination vaccine against both forms is beneficial.
Licence and reuse
Free to read. This article carries the publisher’s copyright, as printed on it: © 2008 Science Publications. It is free to read; ask us before reusing it.
How to reuse this articleResponses (0)
About this article
Connor, B. A., Anderson, S. & Steffen, R. (2008). The Use of a Combination Vaccine in International Travelers Visiting Countries with High Endemic Rates of Hepatitis A and/or Hepatitis B. American Journal of Infectious Diseases, 4(2), 104–108. https://doi.org/10.3844/ajidsp.2008.104.108
- Licence
- © Science Publications
- Issue
- Volume 4, Issue 2
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record
